India and South Africa’s recent submission seeking a waiver from the “implementation, application and enforcement” of certain provisions of the Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) for COVID-19-related therapeutics and vaccines has brought the debate over intellectual property rights (IPR) center stage again, with some experts warning that the risk for pharma lies if potential measures "creep" into other areas.
Can India, S Africa COVID IPR Waiver Request Gain Traction?
A proposal from India and South Africa to unlock patents on COVID-19 medicines and tools has put the spotlight back on intellectual property rights issues. Pharma may want to keep a close eye on progress, especially if momentum builds or issues are left open-ended.
